U-genes Biotechnology Co., Ltd. is excited to announce our participation in RNATx 2026: RNA Therapeutics — From Concept to Clinic, taking place from June 24–26, 2026.
As RNA therapeutics continue to move from early discovery toward clinical application, the demand for reliable, high-quality, and customizable nucleic acid chemistry materials has never been more important. At U-genes, we are proud to support this fast-evolving field with a comprehensive portfolio of oligonucleotide building blocks and synthesis solutions.
At RNATx 2026, U-genes will showcase our capabilities in modified nucleosides and nucleotides, phosphoramidites, CPG and polystyrene solid supports, GalNAc-related materials, chemical linkers, fluorescent dyes, quenchers, labeling reagents, and custom synthesis services. These products are designed to support researchers, biotech companies, diagnostic developers, and therapeutic innovators working across the RNA and oligonucleotide landscape.
RNATx 2026 brings together leading voices from academia, biotechnology, pharmaceuticals, and clinical development. For U-genes, it is more than an event — it is an opportunity to exchange ideas, understand emerging needs, and build stronger connections with partners shaping the next generation of RNA medicines.
We look forward to meeting customers, collaborators, and new friends at RNATx 2026, and to exploring how U-genes can help turn promising RNA concepts into practical, scalable, and impactful solutions.
